From Contract Access to Sustainable Government-Channel Revenue

A contract vehicle creates purchasing access. It does not create clinical adoption, demand, or revenue.

Federal healthcare can be an attractive growth channel for medical device companies. The Department of Veterans Affairs (VA), Department of Defense (DoD), Defense Health Agency (DHA), and Indian Health Service (IHS) serve large, clinically diverse patient populations and purchase products across capital equipment, implants, diagnostics, medical-surgical supplies, laboratory products, software, and services.

But federal market entry is often approached backward.

Companies begin by asking, “How do we get on the Federal Supply Schedule?” or “Do we need an ECAT contract?” Those are important questions, but they are not the first questions.

The better question is:

How will each target customer evaluate, purchase, adopt, distribute, support, and continue using our product?

That answer determines the right acquisition pathway—and whether the organization can convert a contract award into sustainable revenue.

Successful federal commercialization requires three forms of access to work together:

Access requirement	The executive question
Contract access	Can the agency legally and efficiently purchase the product?
Clinical access	Will the product clear clinical review, evidence, standardization, technology, training, and stakeholder requirements?
Operational access	Can the company quote, fulfill, support, invoice, forecast, administer, and maintain the business?

Most underperforming federal programs are not missing all three. They are missing one—and that is enough to stall growth.

This is why federal growth should be managed as an enterprise operating model, not assigned narrowly to Sales or Contracts. Leadership must connect market priorities, product strategy, contract acquisition, pricing, partner development, pipeline governance, fulfillment, compliance, and executive reporting around a shared roadmap.

Start With the Customer, Not the Contract Vehicle

“Federal healthcare” is not one market. VA, DoD/DHA, and IHS operate under federal acquisition rules, but they do not have identical missions, clinical priorities, purchasing structures, or routes to adoption.

Department of Veterans Affairs

The VA is an integrated healthcare system, but purchasing and clinical adoption can involve national, Veterans Integrated Service Network, and facility-level stakeholders. Product availability through a contract does not eliminate clinical product review, equipment planning, standardization, information-security review, value analysis, budget constraints, or local implementation requirements.

For many devices, success depends on mapping the full decision system:

Who owns the clinical problem?
Which committee or functional group reviews the product?
Is the product treated as a clinical supply, implant, capital asset, prosthetic item, laboratory product, software solution, or service?
Is funding controlled nationally, regionally, or locally?
What evidence and economic case will the clinical and administrative stakeholders require?
What training, credentialing, service, data integration, or post-sale support is necessary?

VA guidance assigns clinical-product and equipment-review responsibilities to formal facility and network processes. A purchasing vehicle may make the product orderable; it does not make it clinically preferred or operationally ready.

Department of Defense and Defense Health Agency

The DoD/DHA market includes military treatment facilities, operational and readiness requirements, DLA purchasing programs, and other component- or requirement-specific acquisitions. The appropriate pathway depends on the product category, intended user, care setting, demand profile, logistics requirements, and solicitation.

For a manufacturer, the strategic issue is not simply “DoD access.” It is identifying:

The clinical or readiness requirement the product addresses
The facilities, commands, or programs that create demand
The acquisition organization and contracting pathway
The distributor, catalog, or logistics infrastructure involved
Any cybersecurity, information-handling, supply-chain, or deployment requirements

DoD cybersecurity obligations must be evaluated against the actual solicitation and information environment. CMMC, DFARS, and NIST requirements should not be treated as a generic box that applies identically to every product or transaction.

Indian Health Service

IHS should not be treated as a smaller version of the VA. Its acquisition environment includes Headquarters, Areas, Service Units, the National Supply Service Center, local clinical needs, and procurement conducted under federal and IHS-specific policy.

The Buy Indian Act authorizes procurement preferences for qualified Indian-owned and controlled businesses and is a meaningful part of IHS market-entry planning. Manufacturers should evaluate the end customer, acquisition authority, geography, eligible partners, product-support model, and specific purchase route rather than assuming that a VA or DoD strategy will transfer unchanged.

Choose the Acquisition Pathway That Matches Buying Behavior

There is no universally “best” federal contract vehicle. The right route depends on what is being sold, who is buying it, how often it is purchased, whether distribution is required, and how the agency wants to transact.

VA Federal Supply Schedule

The VA administers multiple-award Federal Supply Schedule contracts for medical products and services under authority delegated by the General Services Administration. These contracts support VA and other eligible federal purchasers.

For MedTech manufacturers, FSS readiness typically requires more than completing an application. The company must be prepared to support:

Commercial Sales Practices and pricing disclosures
Negotiated federal pricing
Tracking-customer or basis-of-award governance, when applicable
Price Reductions Clause monitoring
Trade Agreements Act and country-of-origin requirements applicable to the offering
Contract modifications, sales reporting, fees, and ongoing administration
Product additions, deletions, substitutions, and economic price adjustments

The strategic risk is not merely submitting inaccurate data. It is entering negotiations before the commercial business has disciplined pricing, reliable transaction data, defined customer classes, and clear discount authority.

If commercial pricing is inconsistent, federal negotiations will expose it.

DLA Electronic Catalog

The Electronic Catalog, or ECAT, is a DLA electronic ordering, distribution, and payment platform through which DoD and other authorized federal customers can access negotiated commercial catalogs. DLA negotiates discounted catalog pricing presented to customers as a total delivered price, including applicable distribution, transportation, and administrative costs.

ECAT can be well suited to portfolios where customers benefit from catalog visibility, product comparison, global ordering access, and a structured delivered-price model. But ECAT participation still requires active management of:

Catalog accuracy and item maintenance
Delivered-price economics
Distribution and fulfillment performance
Product availability and substitutions
Contract modifications
Customer demand development

An ECAT award makes products visible and orderable. It does not create preference, utilization, or field pull-through.

DAPA and the Medical/Surgical Prime Vendor Program

A Distribution and Pricing Agreement, or DAPA, identifies products and prices that may be distributed through DLA’s Medical/Surgical Prime Vendor Program. It is a pricing agreement—not a standalone procurement contract.

This distinction matters. DAPA success depends on the operating relationship among the manufacturer, DLA, the Prime Vendor, and the customer. A manufacturer must be able to manage:

Product and pricing-file accuracy
Prime Vendor authorization and coordination
Cost, fee, freight, and margin economics
Item additions and maintenance
Demand signals and stocking implications
Order exceptions, backorders, substitutions, and discontinuations
Reconciliation between agreement terms and distributor execution

ECAT and DAPA-supported Prime Vendor access are distinct routes. Selecting one—or pursuing both—should follow customer buying behavior and portfolio economics, not acronym familiarity.

Agency-Specific and Open-Market Opportunities

Not every opportunity starts with FSS, ECAT, or DAPA. Competitive solicitations, blanket purchase agreements, indefinite-delivery vehicles, simplified acquisitions, purchase-card transactions within applicable thresholds, and other agency-specific routes may be relevant.

The mistake is pursuing every available pathway. The objective is to build the smallest viable contract architecture that covers the priority customers and expected purchasing patterns without creating unnecessary administrative burden.

That architecture may include the Federal Supply Schedule, ECAT, DAPA-supported Prime Vendor access, GSA schedules, blanket purchase agreements, indefinite-delivery/indefinite-quantity contracts, or agency-specific solicitations.

Each is a means of reaching a defined customer and purchase pattern—not a trophy for the contract list.

Build a Multi-Year Government Growth Roadmap

A government-channel strategy should translate a broad federal ambition into a sequenced investment plan. Without that roadmap, companies tend to pursue unrelated bids, add contract vehicles faster than they can administer them, and confuse contract activity with market progress.

A practical roadmap connects four horizons:

Horizon	Leadership decisions	Evidence of progress
Prioritize	Select agencies, clinical segments, products, use cases, and target accounts	Defined addressable opportunity and product-channel fit
Establish access	Choose contract vehicles, pricing architecture, distribution, and qualified partners	Awarded or actionable purchasing routes with clear economics
Activate demand	Build clinical advocacy, field coverage, opportunity development, and implementation support	Qualified pipeline, clinical-review progress, and early utilization
Scale performance	Expand contracts, improve forecasting, manage renewals, and optimize partner and account performance	Repeatable growth, forecast accuracy, margin discipline, and retention

The roadmap should explicitly identify what the company will not pursue.

A bid/no-bid decision is a resource-allocation decision. It should consider strategic fit, customer access, probability of award, compliance burden, price and margin requirements, operational readiness, partner dependence, and post-award cost to serve.

A large pipeline filled with weakly qualified federal opportunities is not evidence of growth. It is deferred disappointment.

Federal Pricing Must Be Designed—Not Improvised

Federal pricing is not simply “commercial price less a government discount.” It is a governed architecture connecting commercial transactions, customer classes, channel economics, federal disclosures, contract terms, and ongoing monitoring.

A defensible model should answer six questions:

1. What is the commercial benchmark?

The company must understand actual transaction behavior—not just list price or intended policy.

2. Which customers are genuinely comparable?

Customer classification must reflect differences in volume, commitments, services, distribution, product mix, geography, and economics.

3. What does the federal price include?

Freight, distribution, administrative fees, installation, training, service, software, accessories, and other elements must be explicitly mapped.

4. Who can approve exceptions?

Discount authority, escalation thresholds, documentation, and expiration dates must be controlled.

5. How will commercial changes be monitored?

A pricing decision made in the commercial channel can create federal disclosure, negotiation, or Price Reductions Clause implications.

6. Can the company preserve margin after award?

Contract price alone does not determine profitability. Channel costs, cost to serve, freight, service obligations, rebates, fees, and field support must be incorporated.

The most dangerous federal pricing problem often begins outside the federal team: an undocumented commercial exception, a poorly defined customer category, or a distributor concession that no one evaluates for downstream impact.

That is why federal pricing governance must connect Sales, Finance, Contracts, Legal, Compliance, Supply Chain, and Commercial Operations.

Compliance Is an Operating System, Not a Submission Checklist

Companies often assemble the required representations, certifications, disclosures, and product data to win an award, then return ownership to fragmented functions. That approach creates post-award exposure.

The operating model should assign clear ownership for:

FAR, applicable agency supplements, solicitation clauses, and contract terms
Pricing disclosures and Price Reductions Clause monitoring
Trade Agreements Act and country-of-origin substantiation
SAM.gov registration and required certifications
Contract modifications, renewals, and reporting
Cybersecurity and information-handling obligations when applicable
Product, regulatory, quality, and supply-chain documentation
Distributor and subcontractor compliance
Record retention, audit response, and corrective action

The objective is not to make every function a federal-contracting expert. It is to define who makes each decision, what evidence is retained, which systems provide the data, and when an issue must be escalated.

An audit-ready company can reproduce the decision trail. A merely compliant company hopes the right documents can be found.

Build the Lead-to-Order Operating System

Federal revenue can break down at the handoffs between business development, contracting, quoting, distribution, order management, and finance. A credible growth plan must address the full lead-to-order flow—not only opportunity capture.

The operating model should define:

How federal leads enter the CRM and are assigned
What evidence is required to advance each pipeline stage
When an opportunity becomes a formal bid/no-bid decision
Who owns proposal strategy, pricing, compliance documents, and final approval
How awarded pricing reaches quoting, distributor, contract, and order systems
How order exceptions, backorders, substitutions, and invoice issues are escalated
How contract utilization, revenue, margin, and renewal risk are reported to leadership

Government bid platforms, CRM, contract repositories, pricing tools, ERP, and distributor data should reinforce one process. Technology cannot rescue unclear ownership or unreliable stage definitions.

A useful executive forecast separates at least six conditions:

Identified: A potential requirement or target account exists.
Qualified: Customer need, acquisition path, timing, competition, and internal fit are understood.
Pursuit approved: Leadership has made a documented bid/no-bid decision.
Submitted or awarded: The contractual event has occurred, but revenue is not yet assumed.
Activated: The product is orderable and the necessary clinical, channel, and operational steps are progressing.
Realized: Orders, shipments, revenue, margin, and utilization are visible in reliable data.

That distinction prevents the most common federal forecasting error: treating a contract ceiling, award, or catalog listing as probable revenue.

Small-Business Partners Can Expand Reach—and Create Risk

SDVOSB, VOSB, 8(a), and other small-business relationships may improve access to eligible opportunities and add customer, contracting, distribution, or service capabilities. But the partner must contribute real value.

Small-business status is not a substitute for a coherent market strategy, and a pass-through relationship can create compliance and performance risk.

Before entering a partnership, leadership should define:

The partner’s certification and eligibility for the target opportunity
The specific work, capabilities, and accountability each party provides
Customer ownership and rules of engagement
Pricing transparency and margin structure
Quoting, ordering, fulfillment, invoicing, returns, and service responsibilities
Data access, forecasting, and performance reporting
Subcontracting limitations and nonmanufacturer-rule considerations
Affiliation or ostensible-subcontractor risk
Exit rights, transition obligations, and protection of active opportunities

For VA opportunities, VOSB and SDVOSB eligibility should be evaluated within the Vets First framework and current SBA certification requirements. For broader federal programs, the applicable set-aside, sole-source, subcontracting, and supply rules must be assessed opportunity by opportunity.

A capable partner extends the operating model. A weakly governed partner obscures it.

The Contract Award Is the Beginning of Commercialization

The first 90 days after award frequently determine whether the contract becomes a growth platform or an administrative asset with little revenue.

1. Activate the Portfolio

Validate awarded products, prices, descriptions, units of measure, and ordering data
Confirm distributor and catalog setup
Establish modification priorities for missing or newly launched products
Resolve pricing, packaging, and product-master discrepancies

2. Activate the Field

Translate contract terms into clear selling and quoting guidance
Identify target facilities, clinical stakeholders, and active requirements
Train the field on what the contract does—and does not—permit
Establish opportunity qualification and bid/no-bid criteria

3. Activate Clinical Adoption

Map evidence, clinical-review, technology, value-analysis, and training requirements
Build the clinical and economic value story for the relevant federal use case
Define implementation, credentialing, service, and post-sale support
Track product-review status separately from contract availability

4. Activate Performance Management

Create federal pipeline stages tied to verifiable customer actions
Reconcile contract, distributor, order, and shipment data
Monitor price realization, margin, product availability, and fulfillment
Establish contract-renewal and modification calendars
Review partner performance and channel conflict

The leadership dashboard should distinguish contracted, orderable, clinically approved, forecasted, ordered, and fulfilled revenue. Treating those as one pipeline stage creates false confidence.

At the executive level, the dashboard should also show:

Pipeline value by agency, product, stage, and expected timing
Win rate, sales-cycle duration, and bid/no-bid conversion
Contract utilization versus addressable opportunity—not merely contract ceiling
Forecast accuracy and slippage
Price realization, gross margin, and cost to serve
Product availability, fill rate, and order exceptions
Partner-sourced pipeline and partner performance
Modification, renewal, certification, and compliance deadlines

A Federal Market-Entry Readiness Test

Before committing resources to a contract submission or channel partnership, leadership should be able to answer these questions:

Which agencies, facilities, clinical specialties, and use cases represent the actual addressable opportunity?
Who are the clinical, economic, acquisition, technology, and operational decision-makers?
Which acquisition pathway matches how those customers are expected to buy?
Can commercial and federal pricing coexist without creating avoidable disclosure, price-reduction, or margin exposure?
Are product-origin, cybersecurity, supply-chain, registration, and solicitation-specific requirements understood and supported?
Can the organization complete clinical review, implementation, training, fulfillment, invoicing, and post-award support?
Do channel and small-business partners have defined roles, defensible economics, verified eligibility, and measurable accountability?
Who owns federal pricing, contracting, compliance, pipeline governance, partner management, and performance reporting?
What must be true 30, 60, and 90 days after award for the contract to generate revenue?
Which metrics will tell leadership early that the strategy is working—or failing?

If the answers live in separate departments, spreadsheets, or partner relationships, the company is not yet ready to scale.

Build the Federal Business Before Pursuing the Federal Contract

Federal market entry is not a contracting project. It is a commercialization system.

The companies that win sustainably connect market segmentation, clinical adoption, acquisition strategy, pricing governance, compliance, distribution, sales operations, and post-award execution before they overinvest in any single contract vehicle.

Assess Your Federal Market-Entry Readiness

MedConX Advisory helps medical device companies evaluate federal acquisition pathways, build defensible pricing and compliance governance, structure channel partnerships, and operationalize VA, DoD/DHA, and IHS commercialization.

Start a conversation

About the Author

Ed Staten leads MedConX Advisory and has built and operated government-channel, contracting, pricing, and sales-operations programs across MedTech. His experience includes VA and DoD strategy, FSS, ECAT, DAPA, federal pricing governance, partner enablement, pipeline management, and cross-functional execution. His work has helped drive 30% government-sales growth and supported government programs at $10 million scale.

Sources and Further Reading

This article provides strategic and operational guidance and is not legal advice. Requirements should be validated against the current solicitation, contract clauses, regulations, and agency guidance applicable to each opportunity.

Home » Federal Market Entry for Medical Device Companies